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Abstract: Infections remain a significant cause of disease, disability, and death in developing countries. Unfortunately, 
many of these infections, including centuries-old neglected diseases such as malaria and newly emerging and 
re-emerging diseases such as Ebola virus disease (EVD), have limited products available to prevent, diagnose, and treat 
them. One barrier that hinders the development of these products is neglected and emerging disease experts’ limited 
access to the biopharmaceutical industry’s small molecules, technologies, and know-how. Conversely, the biopharma-
ceutical industry’s lack of attention to and expertise in these diseases impedes the development of much-needed prod-
ucts. Organisations are addressing these challenges by developing platforms through which disease experts can access 
industry’s knowledge and assets. Strategic partnerships are applying a synergistic approach to leverage respective 
strengths of academia and industry. The following article describes two open innovation platforms, the Pool for Open 
Innovation against Neglected Tropical Diseases (POINT) and WIPO Re:Search, and two strategic, cross-sector colla-
borative efforts to develop therapeutics for EVD. 
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1. Open Partnerships for Neglected Diseases 
n 2010, the World Health Organization (WHO) 
highlighted 17 bacterial, parasitic, and viral tropi-
cal diseases it deemed to be ‘‘neglected’’ (Table 1). 
These diseases disproportionately affect the poor; 
cause significant morbidity and mortality; and lack 
safe, effective, and affordable drugs, vaccines, and 
diagnostics. Combined, more than a billion individu-
als are infected with one or more of these pathogens[1]. 
Neglected tropical diseases (NTDs) are not only a se-
rious health concern, but also represent a significant 
economic burden on individuals and communities liv-
ing in poverty. The diseases hinder childhood devel-
opment, limit school attendance, and prevent a sub- 
stantial section of the adult population from support-
ing their countries’ economies[2]. For example, it was 
estimated that dengue virus infections in the Americas 
directly and indirectly cost over $2 billion annually[3]. 
NTDs are endemic to over 140 countries worldwide. 
However, the majority of infections occur in low- and 
middle-income countries (LMICs) located in Africa, 
Asia, and Latin America[4]. As such, the economic 
effects of these diseases compound the financial chal-
lenges faced by developing markets and stifle their 
economic advancements.  
Global NTD programs currently focus on innova-
tive and intensified disease management; provision of 
safe water, sanitation, and hygiene practices; vector 
control; veterinary health services; and for those  
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Table 1. List of the 17 neglected tropical diseases defined by 
the World Health Organization. 
Parasitic diseases Bacterial diseases Viral diseases 
Chagas disease Buruli ulcer Dengue fever 
Cysticercosis/Taeniasis Leprosy Rabies 
Dracunculiasis Trachoma  
Echinococcosis Yaws  
Foodborne trematodiases   
Human African trypanosomiasis   
Leishmaniasis   
Lymphatic filariasis   
Onchocerciasis   
Schistosomiasis   
Soil-transmitted helminthiases   
 
diseases with available therapeutics, mass drug ad-
ministration (MDA) programs[4]. In 2012, over 800 
million people received preventive chemotherapy th-
rough MDA programs, and between 2012 and 2013, 
pharmaceutical companies donated over one billion 
treatments for NTD MDA efforts. Through these com-
bined efforts, the incidence of several NTDs has dra-
matically declined. The incidence of human African 
trypanosomiasis declined from 20,499 to 6,314 be-
tween 2003 and 2013[5] and annual new Buruli ulcer 
cases dropped from 5,148 to 2,627 between 2008 and 
2013[6]. Dracunculiasis cases decreased from 63,718 to 
1,797 between 2001 and 2010[7], and with only 148 cases 
reported in 2013, this disease is nearing eradication[4]. 
Despite the pharmaceutical industry’s impressive 
drug donation schemes, companies have historically 
paid little attention to NTDs and other diseases that 
predominantly affect the poor. This is primarily due to 
the perceived inability to secure a return on the large 
investment in research and development (R&D) that is 
needed to bring a medicinal product to the market. As 
a result, there is a significant deficit in modern, safe, 
and effective products for most of the 17 NTDs. 
Furthermore, while pharmaceutical companies have 
the assets and expertise needed to systematically 
discover and develop medicinal products, they lack 
the intricate and in-depth knowledge of the pathogens’ 
biologies and mechanisms of disease that NTD 
researchers have— knowledge that is essential to 
develop treatments for these diseases. 
Many pharmaceutical companies and academic 
institutions have begun answering the plea for NTD 
innovation by developing novel mechanisms and 
programs that remove the barrier of access to the 
assets, knowledge, and expertise of each sector. The 
Pool for Open Innovation against Neglected Tropical 
Diseases (POINT) is one example of such a program. 
Established in 2009 by GlaxoSmithKline (GSK), 
POINT was created to allow universities and 
government research institutes to access GSK small 
molecules, patents, and know-how on favourable 
terms to bolster and accelerate their neglected disease 
therapeutic development. During the development of 
POINT, GSK engaged the non-profit BIO Ventures for 
Global Health (BVGH) to manage the program that 
included over 2,300 patents at its launch. 
The idea of an open innovation platform dedicated 
to accelerating product development for diseases of 
poverty quickly drew interest from the biopharma-
ceutical industry. The demonstration that intellectual 
property (IP) rights can stimulate rather than hinder 
innovation for neglected diseases appealed to a wider 
group of pharmaceutical companies. The World Intel-
lectual Property Organization (WIPO) and its Global 
Challenges division, which focuses on unlocking the 
potential of IP to address the world’s toughest chal-
lenges in the areas of climate change, public health, 
and food security, also expressed interest in exploring 
a new and broader model to exhibit this open access 
concept. WIPO, BVGH, and eight biopharmaceutical 
companies (Alnylam, AstraZeneca, Eisai, GSK, MSD 
[known as Merck & Co., Inc. in the US and Canada], 
Novartis, Pfizer, and Sanofi) were motivated to in-
crease the biopharmaceutical industry’s participation 
in global health, leverage on WIPO’s platform and 
infrastructure, build on the ideas and momentum 
created by POINT, and expand the scope of the pool 
to include diagnostics and vaccines. The common 
commitment and interests led to the establishment of 
the WIPO Re:Search consortium. The goal of WIPO 
Re:Search is to accelerate the development of new 
drugs, vaccines, and diagnostics for NTDs, malaria, 
and tuberculosis by connecting the biopharmaceutical 
industry’s IP assets and resources to qualified academic 
and non-profit neglected disease researchers through 
collaborative research agreements. 
Since its launch in 2011, over 90 for-profit, aca-
demic, non-profit, and government research organisa-
tions from 26 countries have joined WIPO Re:Search. 
Institutions join the Consortium as “User”, “Provider”, 
and/or “Supporter” Members. Provider Members—
most notably the Founding Pharmaceutical Members
—are those organisations that have declared a willing-
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ness to share their IP assets with other Members. User 
Members subsequently utilise these contributed assets 
to accelerate their neglected disease R&D activities. 
Supporter Members join to demonstrate their approval 
of the WIPO Re:Search mission and its innovative and 
open access to IP.  
Drawing on POINT’s access and affordability prin-
ciples, the Consortium and its activities are governed 
by the WIPO Re:Search Guiding Principles. These 
Principles require any products developed through a 
WIPO Re:Search collaboration to be sold royalty-free 
to individuals living in the 49 Least Developed Coun-
tries. WIPO Re:Search Members agree to consider 
access and affordability of products for all other 
developing countries, including those that do not 
qualify as “least developed”, and for regions where 
populations cannot afford treatments. Furthermore, to 
bolster continued neglected disease R&D, the Guiding 
Principles require Members to provide products 
resulting from their collaborations, on a royalty-free 
basis, to other researchers seeking to use these pro-
ducts to advance their own NTD, malaria, and tuber-
culosis R&D. These principles ensure that the prod-
ucts stemming from a WIPO Re:Search collaboration 
is accessible to individuals who need them most[8].  
As the Partnership Hub Administrator of WIPO 
Re:Search, BVGH is responsible for facilitating part-
nerships between Member researchers. Since 2011, 
BVGH has facilitated over 80 research agreements. 
The majority of these agreements involve Members 
sharing compounds and compound libraries with one 
another. For example, MSD has shared a targeted set 
of compounds with researchers from Walter and Eliza 
Hall Institute of Medical Research to screen against 
Plasmodium falciparum and P. vivax, the causative 
agents of malaria. Researchers from University of 
British Columbia agreed to give a selection of com-
pounds with activity against Mycobacterium tuber-
culosis to researchers at the Swiss Tropical and Public 
Health Institute to screen the compounds against M. 
ulcerans, the bacterium that causes Buruli ulcer. In 
addition, other Members have agreed to share confi-
dential data and expertise. GSK provided researchers 
from the Center for World Health & Medicine with 
information and data from its screens of methionine 
aminopeptidase 1 (MetAp-1) inhibitors against M. 
tuberculosis[9]. The National Institutes of Health has 
agreed to provide researchers from the Institut Pasteur 
de Tunis (IP Tunis) with expertise and support to 
improve the thermostability and the freeze-drying 
cycle of a rabies vaccine developed at IP Tunis. Tech-
nologies have also been shared or co-developed 
through WIPO Re:Search. PATH, an international 
non-profit organisation based in Seattle, shared its 
non-instrumented nucleic acid amplification (NINA) 
heater with the Centre Pasteur du Cameroun who will 
incorporate this new technology into novel point-of- 
care diagnostic test systems for malaria.  
In each of these and others WIPO Re:Search colla-
borations, assets, assistance, and expertise were shared 
freely and without financial expectations or obliga-
tions. Furthermore, all WIPO Re:Search collabora-
tions were entered into voluntarily and were directed 
by the Guiding Principles and by mutually agreed- 
upon roles and responsibilities. On average, it can take 
up to 15 years to bring a medicinal product to the 
market[10], so WIPO Re:Search has not yet delivered 
new products for neglected diseases. However, given 
that Member researchers are already seeing their 
product discovery projects advance due to access to 
industry assets[11], it is not overly optimistic to predict 
that the WIPO Re:Search consortium’s goals of 
developing important new products for NTDs will be 
realised in the years to come.  
2. Open Partnerships for Emerging Diseases 
Not all collaborative research efforts for diseases of 
poverty are led by large consortia or coalitions. Dis-
ease-targeted efforts to share assets and expertise be-
tween small groups of organisations are also advanc-
ing product development. The 17 NTDs are not the 
only focus of open and collaborative efforts. The 
covered Ebola virus disease (EVD) epidemic in West 
Africa is the largest since the virus had been dis-
covered in 1976; more than 26,000 individuals have 
been infected, of which over 11,000 have died[12]. The 
swiftness of this epidemic’s spread highlighted the 
dangers of not having effective products to prevent, 
diagnose, or treat infectious diseases, no matter how 
seemingly obscure or distant they are. The 2014–2015 
West African EVD epidemic reignited global interest 
and propelled numerous collaborative efforts focused 
on quickly moving any promising EVD product into 
clinical trials. For example, in April 2014, no vaccine 
for EVD was in clinical trials. Yet a year later, six dif-
ferent EVD vaccines were being tested on humans, 
half of which involved multiple parties from multiple 
sectors (Figure 1). 
Unlike the causative agents of malaria, tuberculosis, 
and NTDs, live Ebola viruses must be handled in 
Jennifer Dent, Katy M. Graef and Paddy Shivanand 
 




Figure 1. Ebola virus disease vaccine development pipeline. The vaccine developer(s), stage of development, and location of clinical 
trial(s) are shown. Information was obtained from the International Clinical Trials Registry Platform (ICTRP) Search Portal[13] and 
from Clinicaltrials.gov[14]. Phase I/II trials are listed as Phase II; Phase II/III trials are listed as Phase III.  
 
high-containment (BSL4) facilities by experienced 
virologists. Given the rarity of BSL4 facilities and the 
specialised training required to handle the deadly virus, 
product developers must collaborate with high-conta-
inment facilities and research experts if their promi-
sing products are to be properly assessed and further 
developed. Kineta, Inc., a biotechnology company in 
Seattle, USA, has developed a portfolio of broadly- 
acting antiviral drugs that activate the innate immune 
system, leading to the inhibition of several viruses—
influenza A and B viruses, West Nile virus, dengue 
virus, human coronaviruses, and respiratory syncytial 
virus—in vitro and in vivo. In order to demonstrate 
similar efficacy against Ebola viruses, Kineta has been 
collaborating with virologists from the University of 
Texas Medical Branch and the Galveston National 
Laboratory—one of only four BSL4 facilities in the 
USA. This synergistic approach is leveraging the re-
spective strengths and assets of each partner to quickly 
drive the development of Kineta’s program forward. 
It is not only research entities that recognise the 
value of open, collaborative research. Funding agen-
cies have begun incorporating requirements for cross- 
sector and transnational partnerships into their funding 
schemes. The Wellcome Trust recently funded a mul-
ti-partner initiative to develop broad-spectrum, fully 
human, therapeutic monoclonal antibodies against 
Ebola viruses. This initiative, co-managed by BVGH, 
is leveraging on the human memory B-cell interro-
gation platform developed by Theraclone Sciences, 
Inc., and the expertise of an array of R&D leaders as 
both project team members and advisors. The consor-
tium is also engaging researchers in the affected West 
African countries to secure access to convalescent 
EVD patients, from which the monoclonal antibodies 
will be derived.  
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While the West African EVD epidemic is winding 
down, these two collaborations highlight the necessity 
of increased communication and collaboration across 
national borders, funding organisations, and R&D 
sectors to form product development partnerships for 
deadly, emerging infectious diseases. 
3. Conclusion 
Given today’s current climate of shrinking R&D 
budgets and increasing demand for quality healthcare 
in developing countries, sharing assets, know-how, 
and data is an efficient and cost-effective means of 
bolstering development of products for diseases that 
primarily affect the world’s poorest. Society has al-
ready embraced the concept of open access and re-
purposing products in other fields. Online databases 
such as Wikipedia share the global combined know-
ledge on topics ranging from history to popular cul-
ture. Society has adopted “upcycling” in an effort to 
minimise its carbon footprint through the reuse of 
gently used consumer goods. Through global con-
sortia such as WIPO Re:Search and other strategic 
partnerships, neglected and emerging infectious dis-
ease researchers are leveraging and applying the bio-
pharmaceutical industry’s expertise and assets to the 
development of drugs, vaccines, and diagnostics for 
diseases of poverty. Biopharmaceutical company com-
pounds that were dismissed due to insufficient activity 
against one indication are being applied to other, more 
neglected diseases. Data are being shared to inform 
neglected disease researchers’ plans and direct their 
R&D activities away from the unnecessary repetition 
of negative experiments. Through these and other ac-
tivities, and increased support for open access from all 
sectors, neglected infectious disease R&D will con-
tinue to expand and prosper. 
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